tbuckley/cabot-search huggingface dataset:
Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo
Authors: Guangyao Lv, Dengjun Sun, Jingwen Zhang, Xiaoxia Xie, Xiaoqiong Wu, Weishuo Fang, Jingwei Tian, Chunhong Yan, Hongbo Wang, Fenghua Fu
Journal: Acta Pharmaceutica Sinica B (2016)

Tubulin has been shown to be an effective target for the development of cytotoxic agents against prostate cancer. Previously, we reported that Lx2-32c is an anti-tubulin agent with high binding affinity to tubulin. In this study, we investigated the potential of Lx2-32c to act as an effective cytotoxic agent in the treatment of prostate cancer. MTT assays showed that Lx2-32c was cytotoxic to all tested prostate cancer cell lines. The Lx2-32c-treated cells typically exhibited a rounded morphology associated with the onset of apoptosis, as evidenced by immunocytochemical staining. Human prostate cancer cell lines treated with Lx2-32c arrest in the G2/M phase of the cell cycle and the treatment is associated with an increased ratio of cells in the sub-G0/G1 phase as determined by flow cytometry. Furthermore, expression of the cleaved form of poly (ADP-ribose) polymerase in prostate cancer cell lines treated with Lx2-32c was shown by Western blotting assay. Xenograft implants of LNCaP and PC3-derived tumors in nude mice showed that Lx2-32c treatment significant inhibited tumor growth with effects equivalent to those of docetaxel. These findings demonstrate the potential of Lx2-32c as a candidate antitumor agent for the treatment of prostate cancer.
Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003)
Authors: Pier Luigi Zinzani, Thomas E. Witzig, Julie M. Vose, Craig B. Reeder, Rena Buckstein, Corinne Haioun, Reda Bouabdallah, Jonathan Polikoff, Pingshan Guo, Annette Ervin-Hayes, Dennis Pietronigro, Jerome B. Zeldis, Myron S. Czuczman
Journal: Blood (2008)
Integrin-binding elastin-like polypeptide as an in situ gelling delivery matrix enhances the therapeutic efficacy of adipose stem cells in healing full-thickness cutaneous wounds
Authors: Seong-Kyoon Choi, Jin-Kyu Park, Jung-Hee Kim, Kyeong-Min Lee, Enjoo Kim, Kyu-Shik Jeong, Won Bae Jeon
Journal: Journal of Controlled Release (2016)
An Explosion Instrument for Disrupting Tissues and Cells
Authors: J A REYNIERS, M R SACKSTEDER
Journal: JNCI Journal of the National Cancer Institute (1960)

A tissue gun (Model A .22 caliber) is described which uses commercially available .22 caliber blank cartridges developed for power tools such as stud drivers and a captive piston to drive tissue through screens of various pore sizes, or through matrices of quartz, carborundum, ceramics, or other abrasive materials. The same method may be used for greater volumes, with a similar apparatus of larger dimensions. With a solid disc, instead of screens, the gun can also be used to apply high pressures of short duration to liquids or cells in suspension as a means of sterilizing them. Heat, gases, and unburned powder do not reach the tissues because of the close tolerance in the construction of the piston. No frothing or heating of the tissues takes place during disintegration. While this gun was designed primarily for use in germ-free isolators, it has much wider applicability in the laboratory. A particular advantage is that both the gun and the cartridges can be sterilized. The gun is made entirely of stainless steel and is sturdily constructed to contain the pressures developed with the cartridges recommended. It is simple to use and involves little time. Safety features have been built into the gun to prevent accidental discharge or to check the piston if an empty gun is fired.
The Chromosomes and Transplantability of Tumors. I. Fundamental Chromosome Numbers and Strain Specificity in Ascites Tumors
Authors: Leo Sachs, Ruth Gallily
Journal: JNCI Journal of the National Cancer Institute (1955)

The Chromosomes and Transplantability of Tumors. I. Fundamental Chromosome Numbers and Strain Specificity in Ascites Tumors Get access Leo Sachs, Leo Sachs Department of Experimental Biology, Weizmann Institute of Science, Rehovoth, Israel Search for other works by this author on: Oxford Academic PubMed Google Scholar Ruth Gallily Ruth Gallily Department of Experimental Biology, Weizmann Institute of Science, Rehovoth, Israel Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 5, April 1955, Pages 1267–1289, https://doi.org/10.1093/jnci/15.5.1267 Published: 01 April 1955 Article history Received: 03 August 1954 Published: 01 April 1955
Red Meat Intake and Risk of ESRD
Authors: Quan-Lan Jasmine Lew, Tazeen Hasan Jafar, Hiromi Wai Ling Koh, Aizhen Jin, Khuan Yew Chow, Jian-Min Yuan, Woon-Puay Koh
Journal: Journal of the American Society of Nephrology (2016)

Randomized controlled trials suggest that protein restriction may retard the progression of CKD toward ESRD. However, the effects of dietary protein intake level and the food sources of dietary protein on the risk of ESRD in the general population remain unclear. We investigated these effects in the Singapore Chinese Health Study, a prospective population-based cohort that recruited 63,257 Chinese adults aged 45–74 years from 1993 to 1998. We collected habitual diet information via a validated semiquantitative food frequency questionnaire and identified ESRD via record linkage with a nationwide registry. In all, 951 cases of ESRD occurred over a mean follow-up of 15.5 years. Regarding total protein intake, compared with the lowest quartile, the three higher quartiles combined had a hazard ratio for ESRD of 1.24 (95% confidence interval [95% CI], 1.05 to 1.46), but the dose-dependent association across the quartiles was not statistically significant ( P trend =0.16). Red meat intake strongly associated with ESRD risk in a dose-dependent manner (hazard ratio for highest quartile versus lowest quartile,1.40 [95% CI, 1.15 to 1.71; P trend &lt;0.001]). Intake of poultry, fish, eggs, or dairy products did not associate with risk of ESRD. In substitution analysis, replacing one serving of red meat with other food sources of protein associated with a maximum relative risk reduction of 62.4% (95% CI, 33.1 to 78.9; P &lt;0.01). Our study shows that red meat intake may increase the risk of ESRD in the general population and substituting alternative sources of protein may reduce the incidence of ESRD.
The “Double” Paradox of Atrial Fibrillation in Black Individuals
Authors: Thomas D. Stamos, Dawood Darbar
Journal: JAMA Cardiology (2016)

Jared W. Magnani, MD, MSc; Faye L. Norby, MS; Sunil K. Agarwal, MD, PhD; Elsayed Z. Soliman, MD, MA, MS; Lin Y. Chen, MD, MS; Laura R. Loehr, PhD; Alvaro Alonso, MD, PhD
Baseline cytokine profiling identifies novel risk factors for invasive fungal disease among haematology patients undergoing intensive chemotherapy or haematopoietic stem cell transplantation
Authors: M. Mansour Ceesay, Shahram Kordasti, Eamaan Rufaie, Nicholas Lea, Melvyn Smith, Jim Wade, Abdel Douiri, Ghulam J. Mufti, Antonio Pagliuca
Journal: Journal of Infection (2016)
Jaccoud’s Arthropathy
Authors: Mittermayer Santiago, Viviane Machicado
Journal: New England Journal of Medicine (2015)

A 58-year-old man presented with systemic lupus erythematosus characterized by polyarthritis, photosensitivity, malar rash, and pleuritis. Despite treatment with glucocorticoids, hydroxychloroquine, and azathioprine, hand deformities, shown in a video, developed over a 10-year period.
Direct Lineage Reprogramming of Murine Fibroblasts to Erythroid Progenitor Cells By Defined Factors
Authors: Sandra Capellera Garcia, Kishori Dhulipala, Kavitha Siva, Violeta Rayon Estrada, Evelyn Wang, Gregory Hyde, Sofie Singbrant, Carl Walkley, Shamit Soneji, Vijay G. Sankaran, Johan Flygare
Journal: Blood (2014)
Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM).
Authors: A. C. Rossi, T. M. Mark, D. Jayabalan, P. J. Christos, F. Zafar, K. Pekle, T. Shore, R. N. Pearse, J. Leonard, S. Chen-Kiang, M. Coleman, R. Niesvizky
Journal: Journal of Clinical Oncology (2011)

8008 Background: Lenalidomide (Rev) has markedly improved survival in patients (pts) with MM. As we gain insight into the long-term effects of this agent, concern has arisen for the possibility of SPM including MDS/AML. Clarithromycin (Biaxin), lenalidomide and dexamethasone (BiRD) was shown to be an effective regimen in symptomatic, newly diagnosed MM. Of 72 patients enrolled, 90.3% had an objective response, 38.9% a complete response (sCR/CR), and 73.6% at least a very good partial response (VGPR). This experience has been compounded by the observation of deepening responses to prolongation of Rev-based therapy beyond induction. All pts have continued to be followed. Methods: Review of all pts charts from the original study with focus on overall survival, progression of disease, time to progression, and development of SPM was completed. Pts were maintained on BiRD until progression of disease, stem cell transplant, or development of intolerable side effects. Results: Long-term follow up demonstrates an overall survival of 82.2% (95% CI 70.7, 89.5) after 4 years. Eleven pts remain on study, while 47 have received second line therapy. Evaluation of SPM in the 68 evaluable pts revealed 11 new diagnoses (incidence of 16%) after an average of 31 cycles (range 3-68) of lenalidomide (BiRd). Six were skin cancers (4 BCC, 2 SCC), 2 colon, 1 prostate, 1 pancreas and 1 metastatic melanoma. Notably, none developed MDS/AML. Mean time to SPM diagnosis was 35 months (range 5-64). Only 7/11 subjects were still on active lenalidomide therapy. Conclusions: BiRD is a highly effective regimen in newly diagnosed MM. In these treatment-naïve pts, no cases of secondary MDS/AML were seen, in contrast to reports in relapse/refractory pts who received Rev as third or fourth line therapy (Reece, Goswami ) or as post-transplant maintenance (Attal , McCarthy). Frequency of SPM is similar to 2010 SEER data for non-MM individuals of similar age. As survival in pts with MM continues to improve, so will our understanding of the long-term effects of novel agents. Design of regular cancer screening programs (derm and GI) of MM pts should be regularly implemented.
Intravenous Immunoglobulin (IVIG) Diminishes Immune-Mediated Clearance of Platelets Expressing an Integrin αIIbβ3 Transgene Product That Restores Hemostasis in a Canine Model for Glanzmann Thrombasthenia.
Authors: Juan Fang, Eric S. Jensen, Lily M. Du, Mary K. Boudreaux, David A. Wilcox
Journal: Blood (2006)
Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study
Authors: Adriana Zingone, Neha Korde, Jinqiu Chen, Liqiang Xi, Mark Raffeld, Beata Holkova, Maciej Kmieciak, Daniel Sullivan, Austin Doyle, Irina Maric, Katherine Calvo, Mary Ann Yancey, Marcia Mulquin, Christina Annunziata, Steven Grant, Ola Landgren
Journal: Blood (2011)
BMA annual meeting: BMA calls for opt-out organ donation to become UK-wide
Authors: Abi Rimmer
Journal: BMJ (2016)

Doctors have called for the BMA to lobby the governments in England, Scotland, and Northern Ireland to implement an opt-out system for organ donation.

In December 2015 a “soft” opt-out system for organ donation was introduced in Wales. Under the new system, if someone has not registered a clear organ donation decision—namely, if they have not opted in or out—they are treated as having no objection to being an organ donor. This …
Abstract 20221: In vivo Implantation of a Functional Tissue Engineered Stentless Pulmonary Valve Using Bone-Marrow-Derived Mesenchymal Stem Cells and Circulating Endothelial Progenitor Cells
Authors: Eva Maria Walter, Virna L Sales, Bjoern Sill, David Martin, Emily Rusk, Sirisha Emani, Roland Hetzer, John E Mayer
Journal: Circulation (2010)
Letter by Dizman et al Regarding Article, “Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study”
Authors: Nazli Dizman, Irem Bozkurt Cakir, Aytekin Oguz
Journal: Circulation (2016)

A Report From the PAROKRANK Study" by Rydén et al 1 with great interest.We congratulate the authors for their meticulous work on such a controversial subject.In our opinion, the title suggests a cause-and-effect relationship between periodontitis and myocardial infarction that has not yet been demonstrated.Case-control studies are not considered to be strong enough to prove causation, although they are well known to be efficient to demonstrate an association between 2 entities. 2 The PAROKRANK study (Periodontitis and Its Relation to Coronary Artery Disease), as a case-control study, would not be able to clarify the causal relationship between periodontitis and first myocardial infarction.In the article and the related editorial, 3 this point is broadly explained by the authors in addition to the potential difficulties of designing a prospective trial to clarify a causality between 2 entities.However, use of the word "increases" might lead to a misconception among readers that this study demonstrates causality.To strengthen the causality power of an observational study, researchers should consider the confounders, reverse causality, and the difference of the exposure between nonrandomized groups. 4 In conclusion, the results of the study represent an association between periodontitis and increased risk, not that periodontitis definitively increases risk of myocardial infarction.
Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,
Authors: Shaji Kumar, Jae Hoon Lee, Juan Jose Lahuerta, Gareth J Morgan, Paul G. Richardson, John Crowley, Jeff Haessler, John Feather, Antje Hoering, Philippe Moreau, Xavier Leleu, Cyril Hullin, Saskia K. Klein, Pieter Sonneveld, David S. Siegel, Joan Bladé, Hartmut Goldschmidt, Sundar Jagannath, Jesus F. San Miguel, Robert Z. Orlowski, Antonio Palumbo, Orhan Sezer, S. Vincent Rajkumar, Brian GM Durie
Journal: Blood (2011)
A case of progressive breathlessness post partum
Authors: Sara Tyebally, Ehsan Ghorani, Baljeet Kaur, Ann Sturdy, Arif Khokhar, Rosemary Fisher, Michael Seckl, Laura Price
Journal: Thorax (2016)

A 35-year-old woman presented with rapidly progressive dyspnoea (WHO functional class III) two months after normal vaginal delivery at term, with no other symptoms. On examination, she was normotensive, with a raised jugular venous pressure, right ventricular (RV) heave, a prominent pulmonary second heart sound and mild pitting leg oedema. Oxygen saturations were 90% on air with a clear chest on auscultation. There was a single enlarged supraclavicular lymph node.

ECG showed sinus tachycardia with right axis deviation. Renal and liver function were normal but brain natriuretic peptide and D-dimer were raised. Chest radiograph showed clear lungs and enlarged proximal pulmonary arteries, with no filling defects or parenchymal disease evident on CT pulmonary angiogram (CTPA). Transthoracic echocardiogram revealed signs of severe pulmonary hypertension (PH) with severely impaired RV function. Right heart catheterisation confirmed precapillary PH with a mean pulmonary artery pressure of 39 mm Hg, pulmonary wedge pressure of 13 mm Hg, cardiac output of 2.1 L/min and pulmonary vascular …
A phase I trial to determine the maximum tolerated dose and evaluate the safety and pharmacokinetics (PK) of docetaxel-PNP, polymeric nanoparticle formulation of docetaxel, in subjects with advanced solid malignancies.
Authors: Kyung Hae Jung, Kyu-Pyo Kim, Dok Hyun Yoon, Yong Sang Hong, Chang-Min Choi, Jin-Hee Ahn, Dae Ho Lee, Jae-Lyun Lee, Min-Hee Ryu, Baek-Yeol Ryoo, Heung-Moon Chang, Tae Won Kim, Sung-Bae Kim, Sang-We Kim, Cheolwon Suh, Yoon-Koo Kang, Jungsin Lee, Kyun-Seop Bae, Yong-Man Kim
Journal: Journal of Clinical Oncology (2012)

e13104 Background: The aim of this study was to determine the maximum tolerated dose (MTD) and recommended dose of docetaxel-PNP when administered every 3 weeks in patients with advanced solid malignancies. Methods: Three to six patients received docetaxel at dose levels of 20-75 mg/m 2 as 60-min infusions every 3 weeks according to the single dose-escalating 3+3 method. Blood samples at the first dose of docetaxel-PNP were collected for PK analysis. Results: Nineteen pts were treated for a median of two cycles (1-14) in the phase I study. Dose escalation was performed up to 75 mg/m 2 . The most frequently reported adverse events were grade 4 neutropenia (52.6%, 10/19), grade 1 myalgia (42.1%, 8/19) and grade 1 alopecia (42.1%, 8/19). No acute infusion reactions were noted. Two dose-limiting toxicity was observed at 20 and 60 mg/m 2 , which were grade 3 hypophosphatemia and death of unknown cause, respectively. Although the MTD was not determined, the recommended dose was determined as 60 mg/m 2 . This was based on neutropenia and PK parameters which are summarized in the table. PK parameters revealed dose linearity. Partial response was seen in one patient and stable disease in seven patients. Conclusions: Administration of docetaxel-PNP was well tolerated up to 60 mg/m 2 every 3 weeks by heavily pretreated patients. Further phase II trials are recommended at this dose level. [Table: see text]
DIAGNOSTIC TESTS FOR PHEOCHROMOCYTOMA
Authors: W SPAETH, W S REVENO
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Case 9-1979
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Arthur R. Clemett, James J. Galdabini
Journal: New England Journal of Medicine (1979)

Presentation of Case First admission. An 84-year-old woman was admitted to the hospital because of jaundice.She was well until three years previously, when a Billroth II operation was performed because of a duodenal ulcer with obstruction of the gastric outlet. Physical examination had revealed hepatosplenomegaly, and the liver appeared cirrhotic at laparotomy. Fourteen months before admission a modified right radical mastectomy was performed because of an infiltrating ductal carcinoma; all 16 axillary lymph nodes resected were free of tumor. During the two months before entry she experienced increasing weakness, anorexia and fatigue and lost 4.5 kg in weight. Her . . .
Hundreds of Genes Experienced Convergent Shifts in Selective Pressure in Marine Mammals
Authors: Maria Chikina, Joseph D. Robinson, Nathan L. Clark
Journal: Molecular Biology and Evolution (2016)

Mammal species have made the transition to the marine environment several times, and their lineages represent one of the classical examples of convergent evolution in morphological and physiological traits. Nevertheless, the genetic mechanisms of their phenotypic transition are poorly understood, and investigations into convergence at the molecular level have been inconclusive. While past studies have searched for convergent changes at specific amino acid sites, we propose an alternative strategy to identify those genes that experienced convergent changes in their selective pressures, visible as changes in evolutionary rate specifically in the marine lineages. We present evidence of widespread convergence at the gene level by identifying parallel shifts in evolutionary rate during three independent episodes of mammalian adaptation to the marine environment. Hundreds of genes accelerated their evolutionary rates in all three marine mammal lineages during their transition to aquatic life. These marine-accelerated genes are highly enriched for pathways that control recognized functional adaptations in marine mammals, including muscle physiology, lipid-metabolism, sensory systems, and skin and connective tissue. The accelerations resulted from both adaptive evolution as seen in skin and lung genes, and loss of function as in gustatory and olfactory genes. In regard to sensory systems, this finding provides further evidence that reduced senses of taste and smell are ubiquitous in marine mammals. Our analysis demonstrates the feasibility of identifying genes underlying convergent organism-level characteristics on a genome-wide scale and without prior knowledge of adaptations, and provides a powerful approach for investigating the physiological functions of mammalian genes.
R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network
Authors: Christiane Pott, Eva Hoster, Kheira Beldjord, Elizabeth A. Macintyre, Sebastian Böttcher, Vahid Asnafi, Reiner Siebert, Anne Plonquet, Evelyne Callet-Bauchut, Vincent Ribrag, Wolfram Klapper, Francoise Berger, Michael Unterhalt, Michael Kneba, Wolfgang Hiddemann, Martin H. Dreyling, Olivier Hermine, Marie-Helene Delfau
Journal: Blood (2010)
Bortezomib Restores Defective Apoptosis by Upregulation of Noxa in Enteropathy-Associated T-Cell Lymphoma
Authors: Laura R de Baaij, Marijn Radersma, Jolanda MW van de Water, Kim BJ Groot, Nathalie J Hijmering, Laura M Moesbergen, Otto J Visser, Joost J Oudejans, Chris JJ Mulder, Chris JLM Meijer, Saskia AGM Cillessen
Journal: Blood (2011)
Design Considerations for Artificial Pancreas Pivotal Studies
Authors: Steven J. Russell, Roy W. Beck
Journal: Diabetes Care (2015)

The development of artificial pancreas systems has evolved to the point that pivotal studies designed to assess efficacy and safety are in progress or soon to be initiated. These pivotal studies are intended to provide the necessary data to gain clearance from the U.S. Food and Drug Administration, coverage by payers, and adoption by patients and clinicians. Although there will not be one design that is appropriate for every system, there are certain aspects of protocol design that will be considerations in all pivotal studies designed to assess efficacy and safety. One key aspect of study design is the intervention to be used by the control group. A case can be made that the control group should use the currently available best technology, which is sensor-augmented pump therapy. However, an equally, if not more, compelling case can be made that the control intervention should be usual care. In this Perspective, we elaborate on this issue and provide a pragmatic approach to the design of clinical trials of artificial pancreas systems.